Free shipping on all orders over $ 500

Pasireotide

Cat. No. M3815
Pasireotide Structure
Synonym:

SOM230

Size Price Availability Quantity
5mg USD 680  USD680 In stock
10mg USD 1040  USD1040 In stock
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
Biological Activity

Pasireotide is a somatostatin analog with a 40-fold increased affinity to somatostatin receptor 5 compared to other somatostatin analogs. Pasireotide (SOM 230) exhibits unique high-affinity binding to human somatostatin receptors sst1/2/3/4/5 with pKi of 8.2/9.0/9.1/<7.0/9.9 respectively. In cultures of human fetal pituitary cells, SOM230 inhibited GH secretion by 42 +/- 9% (P = 0.002) but had no effect on TSH release. SOM230 inhibited GH release from GH-secreting adenoma cultures by 34 +/- 8% (P = 0.002), PRL by 35 +/- 4% from PRL-secreting adenomas (P = 0.01), and alpha-subunit secretion from nonfunctioning pituitary adenomas by 46 +/- 18% (P = 0.34).

Chemical Information
Molecular Weight 1047.21
Formula C58H66N10O9
CAS Number 396091-73-9
Solubility (25°C) DMSO
Storage Powder          -20°C   3 years ;  4°C   2 years
In solvent       -80°C   6 months ;  -20°C   1 month
Conversion of different model animals based on BSA (PMID: 27057123)
Species Mouse Rat Rabbit Guinea pig Hamster Dog
Weight (kg) 0.02 0.15 1.8 0.4 0.08 10
Body Surface Area (m2) 0.007 0.025 0.15 0.05 0.02 0.5
Km factor 3 6 12 8 5 20
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.

References

[1] Thomas J Quinn, et al. Surgery. Pasireotide (SOM230) Is Effective for the Treatment of Pancreatic Neuroendocrine Tumors (PNETs) in a Multiple Endocrine Neoplasia Type 1 (MEN1) Conditional Knockout Mouse Model

[2] Robert D Murray, et al. J Clin Endocrinol Metab. The Novel Somatostatin Ligand (SOM230) Regulates Human and Rat Anterior Pituitary Hormone Secretion

[3] Leo J Hofland, et al. J Clin Endocrinol Metab. The Novel Somatostatin Analog SOM230 Is a Potent Inhibitor of Hormone Release by Growth Hormone- And Prolactin-Secreting Pituitary Adenomas in Vitro

Related Somatostatin Receptor Products
TT-232

TT-232 (CAP-232), a somatostatin derivative, is a peptide SSTR1/SSTR4 agonist.

Cyclosomatostatin

Cyclosomatostatin is a potent somatostatin (SST) receptor antagonist.

Somatostatin-28 (1-14)

Somatostatin-28 (1-14) is an N-terminal fragment of the neuropeptide somatostatin-28.

CH 275

CH 275 is a peptide analog of somatostatin and binds preferably to somatostatin receptor 1 (sst1) with a Ki of 52 nM.

CYN 154806

CYN 154806, a cyclic octapeptide, is a potent and selective somatostatin sst2 receptor antagonist.

  Catalog
Abmole Inhibitor Catalog




Keywords: Pasireotide, SOM230 supplier, Somatostatin Receptor, inhibitors, activators


Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.